PATENT CLAIM ANALYSIS

Application Number: 15938729
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "423000"]

Abstract:
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.

Claim (Index 14):
The compound according to  claim 13 , wherein disorders associated with the oxytocin receptor activity are selected from the group comprising preterm labor, premature birth, dysmenorrhea, premature ejaculation, sexual dysfunction, endometriosis, embryo implantation failure due to uterine contractions, infertility, benign prostatic hyperplasia, neuro-psychiatric disorders, autism, social behavior disorders, psycho-social stress, and/or cardiovascular disorders.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 90.0
- Lexical Diversity: 1.21277
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14479664', '15476325', '14571615', '14735215', '10480992']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7908418344961199
- 35 USC 102 Novelty (BERT): 0.5429120755388629
- Combined Prediction Score: 0.7660488586003942
- Mean Citation Score: 366.683408
- Max Citation Score: 432.80896
- Similarity Product: 222.61549367584232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test